Global TNF Alpha Inhibitors Market Report 2023: Growing Prevalence of Inflammatory Diseases Fuels the Sector

DUBLIN, April 12, 2023 /PRNewswire/ -- The "TNF Alpha Inhibitors Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the market.

The global TNF alpha inhibitors market is expected to grow from $38.56 billion in 2021 to $40.73 billion in 2022 at a compound annual growth rate (CAGR) of 5.6%. The TNF alpha inhibitors market is expected to reach $43.83 billion in 2026 at a CAGR of 1.9%. 

Major players in the TNF alpha inhibitors market are AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A, Novartis International AG, Pfizer Inc., Merck & co. Inc., Janssen Biotech, Ablynx, and Momenta Pharmaceuticals. 

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

The TNF alpha inhibitors market consists of sales of infliximab, adalimumab, etanercept, golimumab, and certolizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

TNF alpha inhibitors refer to medications that are used to treat inflammatory diseases such rheumatoid arthritis (RA), psoriatic arthritis, and juvenile idiopathic arthritis and that help to reduce or eliminate inflammation. TNF inhibitors may have a higher risk for skin cancer, especially non-melanoma skin cancers such as squamous cell carcinoma.

The main types of drugs in TNF alpha inhibitors are remicade (infliximab), enbrel (etanercept), humira (adalimumab), and cimzia (certolizumab pegol), and simponi (golimumab). REMICADE is a prescription drug for persons with slightly too severely active Crohn's disease who haven't had success with other treatments. The different routes of administration include oral, subcutaneous, intravenous, and others and involve various types of diseases such as inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, and ankylosing spondylitis, and others.

The growing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis is a key factor driving the growth of the TNF alpha inhibitors market. Tumor necrosis factor-alpha (TNF alpha) inhibitors are commonly used in gastroenterology, dermatology, and rheumatology for the treatment of various immune-mediated inflammatory diseases.

Globally, the prevalence of inflammatory bowel disease (IBD) is about 0.5-24.5 cases for ulcerative colitis per 100,000 person-years and 0.1-16 cases for Crohn's disease per 100,000 person-years, and overall, IBD prevalence is 396 cases per 100,000 people each year. Thus, the increasing number of cases of inflammatory diseases increases the demand for TNF alpha inhibitors contributing to the growth of the market.

The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market. The multiple adverse effects of TNF alpha inhibition identified by clinical trials and post-marketing surveillance include injection site reactions, neutropenia, infusion reactions, and infections.

According to the U.S. Food and Drug Administration (FDA), TNA alpha inhibitors can cause serious infections in people with weaker immune systems or low resistance levels. The infections can be bacterial, mycobacterial, fungal, and viral leading to various diseases such as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. These side effects force patients to prefer alternatives such as non-TNF biologics, which hampers the growth of the market.

The regions covered in the TNF alpha inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the TNF alpha inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Key Topics Covered:

1. Executive Summary

2. TNF Alpha Inhibitors Market Characteristics

3. TNF Alpha Inhibitors Market Trends And Strategies

4. TNF Alpha Inhibitors Market - Macro Economic Scenario
4.1 COVID-19 Impact On TNF Alpha Inhibitors Market
4.2 Ukraine-Russia War Impact On TNF Alpha Inhibitors Market
4.3 Impact Of High Inflation On TNF Alpha Inhibitors Market

5. TNF Alpha Inhibitors Market Size And Growth
5.1. Global TNF Alpha Inhibitors Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global TNF Alpha Inhibitors Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. TNF Alpha Inhibitors Market Segmentation
6.1. Global TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Remicade (infliximab)
• Enbrel (etanercept)
• Humira (adalimumab)
• Cimzia (certolizumab pegol)
• Simponi (golimumab)

6.2. Global TNF Alpha Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Oral
• Subcutaneous
• Intravenous
• Others

6.3. Global TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Inflammatory Bowel Disease
• Psoriatic Arthritis
• Ulcerative Colitis (UC)
• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Others

7. TNF Alpha Inhibitors Market Regional And Country Analysis
7.1. Global TNF Alpha Inhibitors Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global TNF Alpha Inhibitors Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/xi3cy8

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets